The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksUpdated•Originally published 6 April 2026•Updated 8 April 2026•

1 min read

uniQure (QURE) Faces Lawsuit Over Alleged Data Distortion and FDA Criticism

Fortified uniQure building, fences, caution tape, security cameras. FDA buildings, US flags, justice symbols. Charts on tablets and papers.

Key Facts

1Hagens Berman is updating its investigation into uniQure N.V. (QURE) following rebukes from the U.S. FDA.

2The investigation involves allegations of 'distorted' data and public criticism from FDA officials.

about 2 months ago

Version History

2 additional sources confirmed this story

Version 1about 2 months ago

What changed: The legal status has escalated from an investigation to a formal lawsuit, with a shareholder deadline set for April 13, 2026.

A formal lawsuit has been filed against uniQure N.V. (QURE) following rebukes from officials at the U.S. FDA. The legal action centers on allegations that the company presented "distorted" or misleading clinical data to the public and its shareholders. Law firm Hagens Berman has established a specific deadline of April 13, 2026, for affected shareholders to join the lawsuit and participate in the legal proceedings. This escalation follows public criticism from FDA officials, which has raised significant concerns regarding the transparency of the company's reporting. These developments continue to place downward pressure on QURE stock as investors weigh the risks of litigation and potential legal costs. Analysts are closely monitoring the case's impact on the company's reputation and its ability to secure future regulatory approvals.